International symposium on geroprotectors: Practical Applications of Aging Research for Drug Discovery

Aging lies at the core of every age-related disease and affects every person on the planet. It represents an unbearable toll on the economies of the developed countries resulting in over two trillion dollars in direct medical costs, costs of caring and lost producyo in the US and EU alone. Yet, pharmaceutical companies fail to see the practical applications of aging research as many early experiments with drugs that held promise in slowing the aging processes resulted in commercial failures and write offs. Lack of business models, regulation and absence of a clear set of aging biomarkers make it difficult for large pharmaceutical companies to fully engage in aging research. Unlike other events that are geared towards academia or have a broad range of topics, this forum intends to focus on drug discovery and pharmaceuticals that may have a role in postponing the aging processes, preventing the age-related diseases and evaluating the effectiveness of various small molecules with geroprotective properties.

The event will showcase the research projects in aging research to the leaders of the pharmaceutical industry. The symposium will comprise into the three sessions relevant to the drug discovery companies. Each session will be chaired by the top expert in the field: 

Session I: Predicting the activity of geroprotective drugs: in-silico screening, omics data analysis and rational drug design
Session II: Drugs with the potential geroprotective properties
Session III: Aging Biomarkers: how do we measure aging and geroprotective efficacy?
Session IV: Trends in Aging Research and Drug Discovery.

My dearest friends, please note the schedule update for the Practical Applications of Aging Research for Drug Discovery forum in Basel. Registration is Free. Please use the interactive meeting planner at www.miptec.ch . For more information and forum schedule you may see http://www.agingpharma.org/2014/09/important-forum-schedule-update.html

The forum is organized by Alex Zhavoronkov, PhD  (The Biogerontology Research Foundation, UK) and Bhupinder Bullar, PhD (Novartis Pharma AG, Switzerland)

 It is interesting to note that forum collect so many briliant scientists in one place such as:

Brian Kennedy PhD, Director, CEO, Buck Institute for Aging Research

Charles Cantor PhD, Professor, Boston University

Nir Barzilai, Director, Albert Einstein College of Medicine

Joan Mannick, PhD, Director, Translational Medicine, Novartis Institute for Biomedical Research

Anton Buzdin, PhD, DSc, President, CEO, Pathway Pharmaceuticals, Hong Kong

Joao Pedro De Magalhaes, PhD, Lab Head, University of Liverpool

Alexander Zhavoronkov, PhD, Director, The Biogerontology Research Foundation, CEO, Insilico Medicine, Inc 

Robert Molinari, PhD, CEO, Retrotope, Inc

Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis

Alexey Moskalev, PhD,

DScBhupinder Bhullar, PhD

William Bains, PhD, Head of the SENS Laboratory, Cambridge

Sven Bulterijs, PhD, Post-grad researcher, Yale University

Olga Kovalchuk, PhD, Professor, Lab Head, University of Lethbridge, Director, Canada Cancer and Aging Research Laboratories

Mikhail Blagosklonny, MD, PhD, Professor, Editor-in-Chief of Aging, Cell Cylcle and Oncotarget high-impact journals, Rosewell Park, NY

Blanka Rogina, PhD, Director Genetics & Developmental Biology Graduate Program, University of Connecticut

James Kirkland, MD, PhD, Professor, Mayo Clinic

Barry Merriman, PhD, Professor, UCLA / Lead System Architect, CSO, Thermo Fisher Scientific     

Alexander Bürkle, PhD, Professor, EU MARK-AGE Co-ordinator, University of Konstanz

Vadim Gladyshev, PhD, Professor, Department of Medicine, Harvard Medical School, Director of Redox Medicine, Medicine, Brigham And Women's Hospital, Harvard

Antonei Benjamin Csoka, PhD, Assoc. Professor, Howard University, CEO, Vision Genomics, Inc

Richard Faragher, Professor, University of Brighton 

Geoffrey Furlonger, CEO, Aging Analytics, Charles Groome, Head of Communications, Aging Analytics UK

Dmitry Kaminskiy, Director, Senior Partner, Deep Knowledge Ventures

David Brindley, Research Fellow , Harvard University of Oxford


TOO BAD that i MUST be in Moscow that and other days but my soul and thoughts will be there...

And I promise that I'll try to help in the battel against aging as much as I can.